Vilon Peptide 99%

Vilon Peptide 99% is a synthetic dipeptide (Lys-Glu) from the Khavinson class of bioregulatory peptides developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It is the shortest bioregulatory peptide in the Khavinson system, consisting of only two amino acids. Vilon is designed to target immune (thymic) tissue through proposed peptide-DNA interactions that modulate gene expression in thymocytes and immune cells. As a dipeptide, Vilon tests the minimal boundary of the Khavinson hypothesis - whether even a two-amino acid sequence can carry meaningful tissue-targeting information through its charge distribution and conformational properties.

Shaanxi Medibridge Biotech Co., Ltd. provides research peptides for laboratories, academic institutions, and biotechnology organizations worldwide. As a specialized peptide supplier, we provide lyophilized powder with ≥99% purity verified by HPLC, supported by lot-specific COA, MS/HPLC analytical data, and rigorous impurity control.

Vilon has been investigated for its proposed interactions with gene regulatory regions in immune cells, consistent with the Khavinson bioregulatory dipeptide model. Despite being only two amino acids in length, the Lys-Glu sequence carries a distinctive charge pattern (positive-negative) that may influence electrostatic interactions with DNA. Researchers from the Saint Petersburg group observed that Vilon treatment in lymphocyte culture models was associated with changes in proliferation markers and cytokine expression profiles. Studies suggest that Vilon may influence thymic epithelial cell function, modulating the thymic microenvironment that supports T-cell maturation. In aging models, researchers observed effects on immune competence markers and thymocyte differentiation indices.

Vilon is a short peptide believed to influence cellular aging by selectively loosening facultative heterochromatin, the condensed form of DNA that silences genes needed for normal cell function. By restoring access to these age-suppressed genes, Vilon may reactivate ribosomal RNA synthesis, improve protein production, and support healthier immune activity. Research also suggests it may modulate the CHUK/NF-κB pathway, helping regulate inflammation and immune responses. In addition, early findings indicate that Vilon may help normalize telomere dynamics in lymphocytes. Together, these mechanisms suggest that Vilon acts as a targeted regulator of gene expression rather than a nonspecific cellular stimulant.

Vilon stimulates the proliferative activity of thymocytes, the precursor cells within the thymus that eventually become mature T-cells. In animal models exposed to gamma radiation, which damages the immune system severely, Vilon administration led to measurable thymic recovery.

Histological analyses revealed enlargement of thymic lobules, primarily due to widening of the cortical layer where T-cell maturation occurs. The proliferative index, a measure of how actively cells are dividing, jumped from 26% to 37% with Vilon exposure. That is a 42% increase in cellular proliferation within the thymus.

More importantly, Vilon does not just increase cell numbers. It increases the right kind of cells. Studies show the peptide enhances expression of the CD5 differentiation marker on thymic cells. CD5 is found on mature T-helper cells and cytotoxic T-cells, the two populations most critical for adaptive immunity. Increased CD5 expression indicates that more precursor cells are successfully completing the maturation process, not just dividing aimlessly.

The CD4 molecule marks T-helper cells, the coordinators of immune response. Without adequate CD4+ T-cells, the immune system cannot mount effective responses to new threats, cannot coordinate antibody production, and cannot properly regulate inflammation. Vilon has been observed to increase CD4 molecule expression in thymic cell cultures, indicating enhanced maturation of lymphocyte precursors into functional helper T-cells.

Vilon helps regulate immunity by increasing IL-2 gene expression in splenic lymphocytes, which supports T-cell growth, survival, and activation. At the same time, it can markedly reduce pro-inflammatory cytokine production, helping control excessive inflammation. Through its effect on the CHUK/NF-κB pathway, Vilon appears to balance immune activation and inflammatory restraint, acting as an immunoregulator rather than a simple immune stimulant or suppressor.